What can we learn from fMRI capture of visual hallucinations in Parkinson’s disease?
Objective: To describe the patterns of brain functional changes when visual hallucinations (VH) occur in patients with Parkinson's disease (PD). Background: With disease progression, PD…A Psychometric Analysis of the MDS UPDRS-II and III in Early Parkinson’s disease: Do the Numbers Add Up?
Objective: Our objective was to explore the psychometric evidence for the use of the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part II…A German-Austrian multicenter, non-interventional, prospective study for the treatment with abobotulinumtoxinA injections in naïve and previously treated patients suffering from cervical dystonia
Objective: In this prospective, multicenter, non-interventional study (NCT01840462) the primary objective was effectiveness of abobotulinumtoxinA in BoNT treatment-naïve and previously treated subjects after two injection…Safinamide in Parkinson’s disease
Objective: To evaluate clinical effects, safety and tolerability of safinamide add-on levodopa in Parkinson’s disease (PD) patients. Background: Safinamide is a recently approved adjunctive treatment…Open-label extension (OLE) of a multiple ascending dose (MAD) study of BIIB092 in participants with PSP: Safety analysis
Objective: To assess safety of BIIB092 in participants with progressive supranuclear palsy (PSP) in an OLE of a MAD study. Background: BIIB092 is a humanized…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.